Account
Articles
19.01.2026
If You’re a Market Access Lead in 2026: How to...

The year 2026 marks a significant milestone for the European Union’s (EU) Health Tec...

Read more
News
03.12.2025
Joint Scientific Consultations 2026 – key dates ...

The HTA Coordination Group (HTACG) has now confirmed the 2026 request periods for joint scientific c...

Read more
Insider Insights
26.11.2025
ISPOR Europe 2025: Key Insights, Research Posters ...

ISPOR Europe 2025 brought together global HTA bodies, payers, industry leaders and patient organisat...

Read more
Articles
26.11.2025
2025 Market Access Check-In: Evaluating the Impact...

2025 was a pivotal year for market access, marked by the growing convergence between scientific inno...

Read more
Articles
03.11.2025
Designing Payer-Ready Trials in 2025: Five Decisio...

Clinical innovation has never moved faster. Tools like single-arm designs, novel surrogates, and ada...

Read more
Poster
15.10.2025
What Are the Likely PICOs for Tovorafenib and Lifi...

Objectives:  ​​EUHTA regulation has applied from the 1st January 2025 for oncology pr...

Read more
Poster
15.10.2025
How the EU JCA could interface with Regional Prici...

Objectives: ​​To analyse how the mandatory EU Joint Clinical Assessment (JCA) could in...

Read more
Articles
13.10.2025
Surrogates Under Scrutiny: Proving the Link to Out...

Surrogate Endpoints in HTA Decision-Making The need to stay ahead of competitors and offset losses f...

Read more
Articles
08.10.2025
Orchestrating Evidence Needs: Overcoming Regulator...

Optimising evidence generation in trial design, while navigating regulatory and local payer requirem...

Read more
Guide
08.09.2025
The BRAVE Approach: Your Guide to Early Payer Scie...

Successfully navigating early payer scientific advice whether through Joint Scientific Consultations...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.